Helix BioPharma has positive interim Phase 2 results
February 12, 2010 by leonardzehr · Leave a Comment
The first 10 patients enrolled in Helix BioPharma’s Phase 2 pharmacokinetic study of topical interferon Alpha-2b, in patients with low-grade cervical lesions, have completed the pharmacokinetic primary end point analyses with positive findings. “Given the uniformity of the primary endpoint findings to-date, we intend to conclude patient recruitment for this study once a total of [...]
Listen to BioTuesdays 
